Tacrolimus capsule (low-dose) (DrugBank: Tacrolimus)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
227 | オスラー病 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04646356 (ClinicalTrials.gov) | October 20, 2020 | 20/10/2020 | Tacrolimus Crossover Trial for Hereditary Hemorrhagic Telangiectasia (HHT) | Tacrolimus Crossover Trial for Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed | Drug: Tacrolimus capsule (low-dose);Drug: Placebo | St. Michael's Hospital, Toronto | United States Department of Defense | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | Canada |